Journal article
Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration
AH Kuerec, W Wang, L Yi, R Tao, Z Lin, A Vaidya, S Pendse, S Thasma, N Andhalkar, G Avhad, V Kumbhar, AB Maier
Mechanisms of Ageing and Development | ELSEVIER IRELAND LTD | Published : 2024
Abstract
Nicotinamide mononucleotide (NMN) is a precursor of nicotinamide adenine dinucleotide (NAD), which declines with age. Supplementation of NMN has been shown to improve blood NAD concentration. However, the optimal NMN dose remains unclear. This is a post-hoc analysis of a double-blinded clinical trial involving 80 generally healthy adults aged 40–65 years. The participants received a placebo or daily 300 mg, 600 mg, or 900 mg NMN for 60 days. Blood NAD concentration, blood biological age, homeostatic model assessment for insulin resistance, 6-minute walk test, and 36-item short-form survey (SF-36) were measured at baseline and after supplement. A significant dose-dependent increase in NAD con..
View full abstractGrants
Funding Acknowledgements
The clinical trial is fully funded by Aba Chemicals Co. (Shanghai, China) and Abinopharm, Inc. (Connecticut, USA) . The post hoc analysis was not based on funding.